Deal covers production of fibrinogen.
Crucell entered into a nonexclusive STAR® research license agreement with ProFibrix covering the production of specific forms of human fibrinogen.
According to Crucell, STAR technology is a production method that is particularly useful for the production of recombinant human antibodies and proteins.
